GLP2R Agonists
1 drugsAbout GLP2R
GLP2R (glucagon-like peptide-2 receptor) is a G protein-coupled receptor crucial for intestinal growth and repair. It regulates intestinal function, making it a significant drug target, especially for gastrointestinal disorders.
GLP2R's physiological function makes it a compelling therapeutic target, despite the current lack of direct genetic evidence linking it to specific diseases. Modulation of GLP2R activity holds promise for treating conditions characterized by intestinal dysfunction.
GLP2R is targeted by one FDA-approved drug, GATTEX KIT (Takeda), a peptide-based therapy. This single drug highlights the potential for further exploration of this target in gastrointestinal indications.
Top GLP2R Drugs
Takeda is the only company with an approved drug targeting GLP2R.
Low competition presents an opportunity for new entrants, but also indicates potential challenges in market validation.
GLP2R Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets GLP2R, using peptide modality.
Explore non-peptide modalities to differentiate from existing therapies and expand market reach.
GLP2R Clinical Trials 28 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on GLP2R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 | 100% |
| Phase 2 | 7 | 6 | 0 | 1 | 100% |
| Phase 3 | 15 | 13 | 1 | 1 | 93% |
| Phase 4 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved GLP2R drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting GLP2R. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
GLP2R Drug Approval Timeline (2012 - 2012)
The first and only drug, GATTEX KIT, was approved in 2012.
A single approval over a decade suggests slow progress; new approaches are needed to revitalize the target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 11 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on GLP2R. A trial counts if an approved drug acting on GLP2R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.